Daniel Morgensztern
Overview
Explore the profile of Daniel Morgensztern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
8157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cali Daylan A, Morgensztern D, Waqar S
JAMA Oncol
. 2024 Nov;
11(1):26-27.
PMID: 39541197
No abstract available.
2.
Owen D, Ben-Shachar R, Feliciano J, Gai L, Beauchamp K, Rivers Z, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2442970.
PMID: 39495511
Importance: The National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer suggest that RNA next-generation sequencing (NGS) may improve the detection of fusions and splicing variants compared with...
3.
Morgensztern D, Ready N, Johnson M, Dowlati A, Choudhury N, Carbone D, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5042-5052.
PMID: 39287821
Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated in a phase I...
4.
Auberle C, Gao F, Sloan M, Morgensztern D, Winkler L, Ward J, et al.
J Thorac Dis
. 2024 Jul;
16(6):3782-3793.
PMID: 38983151
Background: Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). The purpose...
5.
Brandt W, Yang Z, Heiden B, Samson P, Morgensztern D, Waqar S, et al.
J Thorac Dis
. 2024 Jun;
16(5):2894-2905.
PMID: 38883676
Background: Large, node-negative but locally invasive non-small cell lung cancer (NSCLC) is associated with increased perioperative risk but improved survival if a complete resection is obtained. Factors associated with positive...
6.
Knapp B, Cittolin-Santos G, Flanagan M, Grandhi N, Gao F, Samson P, et al.
Front Oncol
. 2024 May;
14:1392667.
PMID: 38800383
Introduction: Bone metastases are associated with increased morbidity and decreased quality of life in patients with solid tumors. Identifying patients at increased risk of bone metastases at diagnosis could lead...
7.
Riely G, Wood D, Ettinger D, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2024 May;
22(4):249-274.
PMID: 38754467
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance...
8.
Stevenson J, Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, et al.
J Natl Compr Canc Netw
. 2024 Mar;
22(2):72-81.
PMID: 38503043
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States...
9.
Cittolin-Santos G, Knapp B, Ganesh B, Gao F, Waqar S, Stinchcombe T, et al.
Cancer
. 2024 Mar;
130(14):2453-2461.
PMID: 38470453
Background: Small-cell lung cancer (SCLC) is characterized by rapid proliferation and early dissemination. The objective of this study was to examine the demographic trends and outcomes in SCLC. Methods: The...
10.